Current and future treatment approaches for neuromyelitis optica

Area of Science:

• Neuroimmunology
• Central Nervous System Inflammatory Diseases

Background:

• Neuromyelitis optica (NMO) is a CNS inflammatory disorder causing optic neuritis and myelitis.
• NMO was previously considered a form of multiple sclerosis (MS) but is now recognized as distinct.
• NMO is characterized by B-cell involvement and often associated with anti-aquaporin-4 antibodies.

Purpose of the Study:

• To provide an overview of Neuromyelitis Optica (NMO).
• To review existing therapeutic studies for NMO.
• To propose novel therapeutic strategies for both acute relapses and long-term disease modification in NMO.

Main Methods:

• Literature review of therapeutic studies in NMO.
• Analysis of NMO pathophysiology and disease characteristics.
• Synthesis of data to propose new treatment approaches.

Main Results:

• NMO pathophysiology involves necrotizing vasculitis and B-cell activation.
• NMO is significantly less prevalent than MS, limiting clinical trials.
• Emerging evidence supports immunosuppressive over immunomodulatory treatments for NMO.

Conclusions:

• NMO requires distinct therapeutic strategies from MS.
• Immunosuppressive therapies are indicated for NMO management.
• Further research is needed to develop evidence-based treatment guidelines for NMO.